GU Cancers 2019 | Molecular profiling to identify druggable targets in mCRPC

Axel Heidenreich

Axel Heidenreich, MD, from the University of Cologne, Cologne, Germany, addresses the challenges surrounding the treatment of metastatic castration-resistant prostate cancer (mCRPC). Speaking at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Prof. Heidenreich describes the promising aspects of identifying druggable mutations in mCRPC patients by next-generation sequencing (NGS) in order to develop personalized treatments.

Share this video